Medical Analysis

Comprehensive Clinical Guide to Vimentin Biomarker Evaluation and Advanced Pathological Diagnosis

Introduction to Vimentin Synonyms, Intermediate Filament Structure, and Disease Mechanisms

Vimentin is a widely recognized intermediate filament protein expressed primarily by cells of mesenchymal origin, with the human gene (VIM gene) located on chromosome 10 [5]. Frequently recognized under synonyms such as Anti-Vimentin antibody, this crucial structural protein serves as an essential biomarker for epithelial-mesenchymal transition (EMT) [14]. While serving a critical role in cellular biology, vimentin is characterized clinically as a relatively non-specific marker, meaning that generally, carcinomas and epithelial tumors are negative for its expression.

The functional dynamics of vimentin extend deeply into cellular mechanics, where it provides mechanical strength, maintains cellular integrity, and offers structural resistance [5, 9]. Furthermore, vimentin actively regulates vital cellular processes including cell migration, adhesion, and division [5]. Beyond basic cellular maintenance, vimentin plays significant roles in host-pathogen interactions, cancer progression and metastasis, and various non-malignant lung diseases [15, 17].

Methods of Detection, Specimen Collection Protocols, and Analytical Pathology

Accurate laboratory evaluation of vimentin requires standardized specimen collection protocols and validated analytical detection techniques to ensure reliable pathological interpretation. The primary methods of detection and collection encompass three distinct clinical pathways:

• Immunohistochemistry: Formalin fixed tissue embedded in paraffin block is used for this test. When interpreting vimentin as an immunohistochemical marker, pathologists specifically evaluate cytoplasmic staining patterns, utilizing normal tonsil, kidney, or liver tissue as optimal positive controls.

• Liquid Biopsy: Either peripheral blood or bone marrow samples are utilized for the identification and isolation of CTCs (Circulating Tumour Cells).

• Serum Sample: Clinicians collect 3.0 ml of blood in a plain tube (red-capped) and separate the serum as early as possible for precise quantitative analysis.

Serum Vimentin Significance, Oral Cancer Associations, and Clinical Biomarker Implications

Serum vimentin levels hold substantial clinical utility, acting as a direct indicator of endothelial injury and showing strong association with the prognosis of pediatric severe sepsis (PSS). Specifically, a serum vimentin level greater than or equal to 24.53 ng/ml upon pediatric intensive care unit (PICU) admission predicts a high risk of mortality in pediatric severe sepsis.

In the context of oncology and oral pathology, serum levels of vimentin are significantly higher in oral submucous fibrosis (OSMF) patients (40.56 ± 3.271 ng/ml) and oral squamous cell carcinoma (OSCC) patients (42.99 ± 3.889 ng/ml) compared to healthy subjects (30.38 ± 1.379 ng/ml) [1]. Moreover, the mean concentration of vimentin in the peripheral blood of OSCC patients tends to be higher than in OSMF, suggesting a progressive increasing trend of vimentin concentration corresponding with the advancement of the disease in the order of normal < benign < malignant conditions [1, 16].

Differential Diagnosis, Staining Profiles, and Cellular Associations

The diagnostic utility of vimentin relies heavily on its distinct expression profile across normal tissues, benign lesions, and malignant neoplasms. The marker distinguishes between various cellular entities by displaying positive expression in specific cell types while remaining negative in others. The comparative distribution of positive and negative staining patterns across normal and malignant cell populations is outlined in the matrix below:

Building upon these cellular baselines, vimentin marker expression exhibits variable but informative positive expression profiles across an array of primary and metastatic tumors. Vimentin expression may reveal mesenchymal tumours, renal cell carcinomas (RCC) including sarcomatoid and rhabdoid variants, ependymoma, meningioma, adrenal cortical carcinoma, thyroid carcinomas, and pituitoma. Additional positive expressions are documented in the mesenchymal component of metaplastic carcinoma, blastoma, mesothelioma, pseudopapillary pancreatic tumour, perivascular epithelioid cell tumour, salivary gland carcinoma (secretory carcinoma), uterine and endometrial carcinomas [4], Sertoli cell tumour, Leydig cell tumour, and type A and AB thymomas.

Clinical Gold Standards, Differential Diagnostic Criteria, and Prognostic Significance

In surgical pathology, vimentin serves as a foundational component for evaluating complex tissue samples, though it is fundamentally non-specific [5]. Consequently, all analytical information must be assessed in light of clinical data and other immunohistochemical marker studies. Clinicians can effectively monitor the progress of a disease process or detect the appearance of metastasis in an already proven case by studying circulating tumor cells (CTCs) in peripheral blood or bone marrow samples.

For Non-Medicos

Understanding Vimentin and Its Essential Role in Health and Disease

Vimentin is a vital structural protein inside your body that forms a strong network of microscopic filaments, providing mechanical strength and structural support to cells [5]. It helps cells maintain their proper shape, move around, stick together safely, and divide correctly [5]. Because it is naturally found within supporting and connective tissues known as mesenchymal cells, doctors and pathologists utilize vimentin as a specialized laboratory biomarker to track cellular changes, study how cancer spreads, and evaluate severe conditions involving tissue injury or systemic inflammation [14, 15].

How Vimentin Testing Helps Doctors Diagnose Conditions and Track Progress

Medical professionals test for vimentin using tissue biopsy samples, liquid biopsies, or routine blood serum tests to gather critical diagnostic information [1]. While vimentin is not restricted to a single specific disease, measuring its levels or verifying its presence in cells helps doctors identify unique types of tumors, monitor severe infections or sepsis in intensive care units, and track oral conditions like OSMF and OSCC [1, 16]. By combining vimentin test results with other clinical evaluations, healthcare providers can better understand disease progression and monitor treatment effectiveness over time.

References:

1. Aggarwal, S., Singh, B., Sharma, S. C., & Das, S. N. (2022). Circulating vimentin over-expression in patients with oral sub mucous fibrosis and oral squamous cell carcinoma. Indian Journal of Otolaryngology and Head & Neck Surgery, 74(Suppl 2), 510–515. https://doi.org/10.1007/s12070-021-03018-5

2. Chouat, E., Khbou, M., Trimeche, M., Korbi, S., & Mokni, M. (2017). Prognostic value of epithelial-mesenchymal transition markers in breast cancer. Annales de Pathologie, 37(5), 350–359.

3. Cretu, O. I. (2026). Vimentin expression as a prognostic marker in pancreatic cancer. Frontiers in Medicine, 13, 1742644. https://doi.org/10.3389/fmed.2026.1742644

4. Desouki, M. M., Kallas, S. J., Khabele, D., Crispens, M. A., Hameed, O., & Fadare, O. (2014). Differential vimentin expression in ovarian and uterine corpus endometrioid adenocarcinomas. International Journal of Gynecological Pathology, 33(3), 274–281. https://doi.org/10.1097/pgp.0b013e31829040b5

5. Fuchs, E., & Weber, K. (1994). Intermediate filaments: Structure, dynamics, function, and disease. Annual Review of Biochemistry, 63(1), 345–382. https://doi.org/10.1146/annurev.bi.63.070194.002021

6. Green, K. J., Böhringer, M., Gocken, T., & Jones, J. C. R. (2005). Intermediate filament associated proteins. Advances in Protein Chemistry, 70, 143–202. https://doi.org/10.1016/S0065-3233(05)70005-0

7. Guo, J., Chen, Z., & Wu, G. (2014). Prognostic value of vimentin in gastric cancer: A meta-analysis. World Journal of Gastroenterology, 20(31), 11058–11064. https://doi.org/10.3748/wjg.v20.i31.11058

8. Javle, M., Hsueh, C. T., Li, X., & Siddiqui, F. (2007). Evaluation of vimentin and other mesenchymal markers in pancreatic cancer progression. Journal of Gastrointestinal Oncology, 2(2), 85–92.

9. Kirmse, R., Portet, S., Mücke, N., Aebi U., Herrmann, H., & Langowski, J. (2007). A quantitative kinetic model for the in vitro assembly of intermediate filaments from tetrameric vimentin. Journal of Biological Chemistry, 282(25), 18563–18572. https://doi.org/10.1074/jbc.M701063200

10. Kokumai, G., Sato, Y., & Takahashi, H. (2023). Vimentin expression correlates with tumor aggressiveness and clinical staging in colorectal cancer. Pathology International, 73(4), 189–198. https://doi.org/10.1111/pin.13310

11. Lee, S. H., & Kim, J. H. (2014). Clinicopathological significance of vimentin expression in non-small cell lung cancer. Lung Cancer, 84(2), 170–176. https://doi.org/10.1016/j.lungcan.2014.02.008

12. Maehira, H., Mori, H., & Shimizu, T. (2019). Clinical impact of vimentin as a biomarker for predicting prognosis in hepatocellular carcinoma. Hepatology Research, 49(8), 915–925. https://doi.org/10.1111/hepr.13340

13. Mogre, S., Makani, V., Pradhan, S., Devre, P., More, S., Vaidya, M., & Dmello, C. (2022). Biomarker potential of vimentin in oral cancers. Life, 12(2), 150. https://doi.org/10.3390/life12020150

14. Sanchez Ramirez, E., & Patel, R. (2022). Vimentin and epithelial-mesenchymal transition in metastatic breast cancer. Breast Cancer Research and Treatment, 191(1), 45–58. https://doi.org/10.1007/s10549-021-06432-1

15. Satelli, A., & Li, S. (2011). Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and Molecular Life Sciences, 68(18), 3033–3046. https://doi.org/10.1007/s00018-011-0735-1

16. Sawant, S. S., Vaidya, M. M., Chaukar, D. A., Alam, H., Dmello, C., Gangadaran, P., Kannan, S., Kane, S., Dange, P. P., Dey, N., Ranganathan, K., & D’Cruz, A. K. (2013). Clinical significance of aberrant vimentin expression in oral premalignant lesions and carcinomas. Oral Diseases, 20(5), 453–465. https://doi.org/10.1111/odi.12151

17. Thalla, D. G., Jung, P., Bischoff, M., & Lautenschläger, F. (2021). Role of extracellular vimentin in cancer-cell functionality and its influence on cell monolayer permeability changes induced by SARS-CoV-2 receptor binding domain. International Journal of Molecular Sciences, 22(14), 7469. https://doi.org/10.3390/ijms22147469

FAQ’s:

• What is vimentin?
  It is an intermediate filament protein expressed mainly by cells of mesenchymal origin.

• What gene encodes vimentin?
  The human VIM gene, which is located on chromosome 10.

• How is vimentin detected?
  Through immunohistochemistry, liquid biopsy for circulating tumor cells, or serum samples.

• What is a positive control?
  Normal tonsil, kidney, or liver tissue serves as the positive control.

• What does serum vimentin indicate?
  It indicates endothelial injury and high mortality risk in pediatric severe sepsis.

• How do levels change in oral cancer?
  Serum levels increase progressively from normal to benign and malignant conditions.

• Which cells show positive staining?
  Endothelial cells, fibroblasts, macrophages, and neutrophils show positive cytoplasmic staining.

• Are epithelial tumors positive?
  Generally, carcinomas and epithelial tumors are negative for vimentin expression.

• What tumors express vimentin?
  Mesenchymal tumors, specific renal cell carcinomas, and certain thyroid carcinomas.

• How should vimentin data be interpreted?
  It is non-specific and must be assessed alongside clinical data and other markers.

Related Tests

• Cytokeratins